ACG Wealth’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $6.72M | Sell |
94,513
-2,781
| -3% | -$202K | 1.54% | 13 |
|
|
2022
Q2 | $7.5M | Buy |
97,294
+354
| +0.4% | +$27K | 1.53% | 10 |
|
|
2022
Q1 | $7.08M | Sell |
96,940
-16,746
| -15% | -$1.12M | 1.34% | 13 |
|
|
2021
Q4 | $7.09M | Sell |
113,686
-25,514
| -18% | -$1.5M | 1.01% | 19 |
|
|
2021
Q3 | $8.24M | Sell |
139,200
-168
| -0.1% | -$11.1K | 1.08% | 22 |
|
|
2021
Q2 | $9.31M | Buy |
139,368
+4,108
| +3% | +$268K | 1.18% | 18 |
|
|
2021
Q1 | $8.54M | Buy |
135,260
+9,490
| +8% | +$590K | 1.13% | 17 |
|
|
2020
Q4 | $7.8M | Buy |
125,770
+662
| +0.5% | +$40.7K | 1.08% | 18 |
|
|
2020
Q3 | $7.54M | Sell |
125,108
-3,298
| -3% | -$198K | 1.14% | 16 |
|
|
2020
Q2 | $7.55M | Sell |
128,406
-2,048
| -2% | -$122K | 1.23% | 15 |
|
|
2020
Q1 | $7.27M | Buy |
130,454
+2,515
| +2% | +$154K | 1.35% | 10 |
|
|
2019
Q4 | $8.21M | Buy |
127,939
+55,409
| +76% | +$3.17M | 1.22% | 15 |
|
|
2019
Q3 | $3.68M | Buy |
72,530
+4,662
| +7% | +$219K | 0.54% | 52 |
|
|
2019
Q2 | $3.08M | Sell |
67,868
-30,264
| -31% | -$1.41M | 0.41% | 63 |
|
|
2019
Q1 | $4.68M | Buy |
98,132
+9,464
| +11% | +$471K | 0.63% | 39 |
|
|
2018
Q4 | $4.61M | Buy |
88,668
+29,988
| +51% | +$1.61M | 0.71% | 35 |
|
|
2018
Q3 | $3.64M | Sell |
58,680
-325
| -0.6% | -$19.3K | 0.48% | 52 |
|
|
2018
Q2 | $3.27M | Buy |
59,005
+39
| +0.1% | +$2.11K | 0.49% | 53 |
|
|
2018
Q1 | $3.73M | Buy |
58,966
+3,608
| +7% | +$232K | 0.56% | 47 |
|
|
2017
Q4 | $3.39M | Buy |
55,358
+2,332
| +4% | +$146K | 0.5% | 53 |
|
|
2017
Q3 | $3.38M | Sell |
53,026
-5,244
| -9% | -$306K | 0.59% | 46 |
|
|
2017
Q2 | $3.25M | Sell |
58,270
-826
| -1% | -$44.9K | 0.53% | 49 |
|
|
2017
Q1 | $3.21M | Buy |
59,096
+13,702
| +30% | +$752K | 0.59% | 49 |
|
|
2016
Q4 | $2.65M | Sell |
45,394
-6,471
| -12% | -$354K | 0.56% | 52 |
|
|
2016
Q3 | $2.8M | Buy |
51,865
+5,177
| +11% | +$333K | 0.6% | 46 |
|
|
2016
Q2 | $3.43M | Buy |
46,688
+220
| +0.5% | +$15.5K | 0.76% | 35 |
|
|
2016
Q1 | $2.97M | Buy |
46,468
+30,717
| +195% | +$1.94M | 0.67% | 39 |
|
|
2015
Q4 | $1.08M | Buy |
15,751
+522
| +3% | +$34.5K | 0.24% | 99 |
|
|
2015
Q3 | $902K | Buy |
15,229
+895
| +6% | +$56.8K | 0.24% | 91 |
|
|
2015
Q2 | $954K | Buy |
14,334
+89
| +0.6% | +$5.87K | 0.24% | 94 |
|
|
2015
Q1 | $919K | Sell |
14,245
-909
| -6% | -$56.9K | 0.24% | 99 |
|
|
2014
Q4 | $894K | Buy |
15,154
+108
| +0.7% | +$6.09K | 0.24% | 93 |
|
|
2014
Q3 | $770K | Sell |
15,046
-2,700
| -15% | -$135K | 0.22% | 100 |
|
|
2014
Q2 | $861K | Sell |
17,746
-200
| -1% | -$9.86K | 0.16% | 103 |
|
|
2014
Q1 | $932K | Sell |
17,946
-400
| -2% | -$21.3K | 0.28% | 87 |
|
|
2013
Q4 | $975K | Sell |
18,346
-1,754
| -9% | -$89.3K | 0.25% | 89 |
|
|
2013
Q3 | $930K | Buy |
20,100
+300
| +2% | +$13.2K | 0.38% | 68 |
|
|
2013
Q2 | $885K | Buy |
+19,800
| New | +$860K | 0.35% | 72 |
|
Other funds holding BMY
ACG Wealth's BMY Position: Q3 2022 in Review
ACG Wealth reduced its Bristol-Myers Squibb (BMY) stake by 2.9% in Q3 2022, selling an estimated $202K and leaving 94,513 shares worth $6.72M. The position accounts for 1.54% of the portfolio, ranked #13.
ACG Wealth first reported a position in BMY in Q2 2013 and has held it in 38 quarters since. The position peaked at $9.31M in Q2 2021. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.
- ACG Wealth held 94,513 shares of Bristol-Myers Squibb worth $6.72M as of Q3 2022.
- ACG Wealth sold 2,781 Bristol-Myers Squibb shares in Q3 2022, an estimated $202K.
- Bristol-Myers Squibb made up 1.54% of ACG Wealth's portfolio in Q3 2022, its #13 holding.
- ACG Wealth first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 38 quarters since.
- ACG Wealth's Bristol-Myers Squibb position peaked at $9.31M in Q2 2021.
- 2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.
Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.